Citron Research Raises The Caution Flag On Amedisys (AMED)

Today, Citron Research issued a negative report on Amedisys (Nasdaq: AMED). First, Citron Research is an outlet that does much due diligence to learn if there is any dubious activity occurring at a company. For example, Citron wrote extensively writing about ArthroCare Corporation (Nasdaq: ARTC) margins not adding up and just last month ArthroCare announced it had restate earnings and ARTC fell by more than 50% in like kind.

Next up: Amedisys. Citron uncovers startling stories through extensive research. For example, Citron's private investigators spoke to ex- Amedisys employees who admitted to altering OASIS scores to increase billings. Further, the report said local Amedisys offices would receive calls from headquarters to alter scores on Medicare patients in order to justify the higher billings. However, Citron does emphasize that it has not concluded that Amedisys has committed any Medicare fraud, but the implications require deeper scrutiny.

The Citron report on Amedisys is a must read and can be read here.

Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News Today!

You May Also Be Interested In

• Senior Iranian Official To Reuters: Iran Will Make No Concessions On Its Nuclear Program
• Araghchi gave Witkoff and Kushner Iran's conditions for reopening the Strait of Hormuz and resuming nuclear talks - Axios
• Blue Origin Raises $10B At $140B Valuation - WSJ